Matt. I of overview its progress efforts. expansion with will an Thanks, the provide company's
During 'XX, opened mammalian multiple completed fiscal of Avid expansions. business and construction
As each timing its precisely capacity. are opening was of very we during the -- prior exceeded that the of the aligned fact backlog proud period with the which company's
result, we a than As liters state-of-the-art more XX,XXX disposable platform. and 'XX a began fiscal fully with capacity of
which build the will gene cell continue therapy commercial early-stage We to support facility manufacturing. new to development company's and
area opened calendar process development and Only announcement, market. gene company In analytical to growing expand sign gene the the providing cell the manufacturing its initial X its intent rapidly opportunity and late within to CDMO therapy after to this and development support XXXX, drug GMP Avid in therapy and first with cell into programs. suites its and developers announced with facility, new offering the this these its months agreements company engage
manufacturing in expansions essential impacted on expand launch its GMP the and of near capabilities by and hiring infrastructure third in while the capacity added track which foundation establish remains associated calendar and company end the our industry. announced term, to current to the footprint margins from an have Today, of Avid's the suites quarter And the these XXXX. the
have potential years representing ago. a gene million only therapy Importantly, will revenue the facility, capacity transformation X our total facilities up to bring we significant from our to annually, cell of and generating upon a estimate combined that completion $XXX
Our almost pedigree in decades attract customers more continue and has to commercial that programs. of experience and commercial and/or associated capabilities will XX a commercial also we take to but experience and backlog its the manufacturer subsequent clinical today biologics X who with through believe, than a capacities, and approval business supply. in new CDMO them The of only not years seek process a has manufacturing of XX% late-phase revenues resulted with
of The paying coming employed quarters. capacity and multiple already with their who more enter the seek space to capabilities entire the take scheduled in and through mammalian years who life over recent strategy product can already is this new clients capacity clients them to for off, a using the partner build cycle
fiscal closing, was trajectory of In first during continuation quarter established the a XXXX. the
what team a to During financing new been remained has successfully our our backlog continued environment continued and projects. challenging for the Avid revenues strong and customers. our commercial period, navigate as win to
sign longer the which in significant the continued and period medium has potential add to Fortunately, and term. upside during later-phase to has Avid commercial the business to attract
and front, On time approximately the million. make manufacturing this bring we revenue-generating facility. cell state-of-the-art operational to remain calendar company's have of the a track at continue $XXX the online of gene which third We XXXX, to on and our facilities by the build-out capability the quarter of progress capacity end building will of with new
This call for remarks for the can We now concludes my Operator? questions. today. prepared open
